CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Elderly cancer patientsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03676218
NCT03676218N/ACompleted

Assessing Patient-reported Outcomes (PROs) and Patient-related Outcomes in Randomized Cancer Clinical Trials for Older Adults: the DATECAN-ELDERLY Initiative

Institut Bergonié·observational·Posted Sep 18, 2018·Updated Oct 3, 2025

In Brief

An observational study evaluating Elderly cancer patients for Cancer. Completed, enrolled 14 participants across 1 site.

Detailed Summary

As older adults with cancer are underrepresented in randomized clinical trials (RCT), there is limited evidence on which to rely for treatment decisions for this population. Commonly used RCT endpoints for the assessment of treatment efficacy are more often tumor-centered (e.g., progression-free survival). These endpoints may not be as relevant for the older patients who present more often with comorbidities, non-cancer-related deaths, and treatment toxicity. Moreover, their expectation and preferences are likely to differ from younger adults. The DATECAN-ELDERLY initiative combines a broad expertise, in geriatric oncology and clinical research, with interest in cancer RCT that include older patients with cancer. In order to guide researchers and clinicians coordinating cancer RCT involving older patients with cancer, the experts reviewed the literature on relevant domains to assess using patient-reported outcomes (PRO) and patient-related outcomes, as well as available tools related to these domains. Domains considered relevant by the panel of experts when assessing treatment efficacy in RCT for older patients with cancer included functional autonomy, cognition, depression and nutrition. These were based on published guidelines from international societies and from regulatory authorities as well as minimum datasets recommended to collect in RCT including older adults with cancer. In addition, health-related quality of life, patients' symptoms, and satisfaction were also considered by the panel. With regards to tools for the assessment of these domains, we highlighted that each tool has its own strengths and limitations, and very few had been validated in older adults with cancer. Further studies are thus needed to validate these tools in this specific population and define the minimum clinically important difference to use when developing RCTs in this

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesFrance

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 18, 2018
Enrollment StartSep 1, 2017
Primary CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 7.8 years ago

Interventions

Elderly cancer patientsother

No intervention: Panel of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.